Rachel Humphrey - Oct 21, 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Oct 21, 2021
Transactions value $
$0
Form type
3
Date filed
10/21/2021, 08:41 PM
Next filing
Aug 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding XLO Common Stock 9.44K Oct 21, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Stock Option (right to buy) Oct 21, 2021 Common Stock 14.2K $5.51 Direct F1
holding XLO Stock Option (right to buy) Oct 21, 2021 Common Stock 34.5K $5.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on July 23, 2020 for 14,239 shares. One-third of the shares vested on December 13, 2020, and one third of the shares shall vest on December 13, 2021 and December 13, 2022, respectively.
F2 The option was granted on March 11, 2021 for 34,450 shares. On March 11, 2021, 10,048 shares underlying the option vested, with the remainder scheduled to vest in equal monthly installments on the 13th of each month thereafter over the following 34 months.

Remarks:

Exhibit Index: 24.1 Power of Attorney